204 2nd Avenue
31 articles with Augmenix
Boston Scientific Corporation today announced the close of its acquisition of Augmenix, Inc., a privately-held company that developed and commercialized the SpaceOAR® Hydrogel System to help reduce common and debilitating side effects that men may experience after receiving radiotherapy to treat prostate cancer.
Acquisition expands portfolio of men's health in-office procedures with adjunctive therapy for prostate cancer patients
Augmenix K.K. announces that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all prostate cancer radiotherapy patients in Japan through the Ministry of Health, Labour & Welfare (MHLW) national reimbursement.
Augmenix, Inc. Announces Exciting Plans for the 2018 American Urological Association Meeting in San Francisco
Augmenix, Inc. is pleased to announce that they will be exhibiting at this year’s American Urological Association meeting in San Francisco, California. Located at Booth 6251 Hall D, the company will be featuring their leading product, SpaceOAR® hydrogel, which is used in patients receiving radiation therapy for prostate cancer.
Augmenix, Inc. is pleased to announce that the Geisinger Health Plan and the military payer TRICARE have joined the growing list of insurers now covering the company’s leading product, SpaceOAR hydrogel.
Augmenix, Inc. has opened a new company headquarters, Augmenix KK., in Japan.
Augmenix, Inc. Announces Aetna’s Positive Coverage Decision for the SpaceOAR Hydrogel Procedure for Men with Prostate Cancer
Augmenix is pleased to announce that Aetna, Inc, the third largest commercial health plan provider in the United States.
Augmenix Announces Medicare Reimbursement Rates for the New CPT Code 55874, Which Will be Used to Bill SpaceOAR Hydrogel, Effective January 2018
The code, which goes into effect January 1, 2018, will enable both hospitals and physicians to receive payment.
Augmenix Partners With Us TOO International To Stream Live Webcast And Q & A On Prostate Cancer Radiation Therapy
Augmenix Announces Positive Clinical Trial Results Demonstrating Efficacy Of Spaceoar Hydrogel In Patients Undergoing Dose-Escalated Stereotactic Body Radiation Therapy For Prostate Cancer
Augmenix To Unveil New Clinical Data On Its Innovative Absorbable Hydrogel Technology At The 59th Annual Meeting Of The American Society For Radiation Oncology
Augmenix Announces Positive Five-Year Long-Term Data Highlighting Significant Bowel And Sexual Quality Of Life Benefits For Prostate Cancer Patients Treated With Spaceoar Hydrogel
Augmenix Release: NICE Announces Interventional Procedure Guidance Supporting Use Of Hydrogel Spacer In Treatment Of Prostate Cancer In The UK
Augmenix Release: Phase 3 Trial Data Show Use Of SpaceOAR Hydrogel Helps Maintain Erectile Function Following Prostate Cancer Radiation Treatment
Augmenix Release: Company Announces Positive Three-Year Long-Term Data Highlighting Benefits Of Spaceoar Hydrogel Spacer For Patients With Prostate Cancer
Augmenix Announces New Category 1 CPT Code From The American Medical Association For Periprostatic Implantation Of Biodegradable Material
Augmenix Announces Positive Spaceoar Clinical Trial Results Demonstrating Superior Outcomes At 3-Years